ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended																		0 Months Ended
	Dec. 31, 2013 Item	Dec. 31, 2013 Minimum	Dec. 31, 2013 Minimum Managed Care Rebates	Dec. 31, 2013 Minimum Medicare Part D Coverage Gap Rebates	Dec. 31, 2013 Maximum	Dec. 31, 2013 Maximum Managed Care Rebates	Dec. 31, 2013 Maximum Medicare Part D Coverage Gap Rebates	Dec. 31, 2013 Gralise Minimum	Dec. 31, 2013 Gralise Maximum	Dec. 31, 2013 Zipsor	Dec. 31, 2013 500mg Glumetza	Dec. 31, 2013 1000mg Glumetza Minimum	Dec. 31, 2013 1000mg Glumetza Maximum	Dec. 31, 2013 CAMBIA Minimum	Dec. 31, 2013 CAMBIA Maximum	Dec. 31, 2013 Lazanda Minimum	Dec. 31, 2013 Lazanda Maximum	Dec. 31, 2013 Liability related to sale of future royalties	Oct. 18, 2013 Liability related to sale of future royalties PDL BioPharma
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Number of product candidates under clinical development	1
Summary Of Significant Accounting Policies
Royalty and milestone payments received	$ 240,500																	$ 240,500	$ 240,500
Product return period prior to expiration					6 months
Period after expiration for accepting unsalable product					12 months
Product shelf-life								24 months	36 months	36 months	48 months	24 months	36 months	24 months	48 months	24 months	36 months
Discount taken off period after the quarter in which product shipped to the customer		1 month			2 months
Cash discount (as a percent)	2.00%
Discount reimbursement period after filling of prescription subject to discount	1 month
Period after the quarter in which prescription is filled for paying rebate		2 months			3 months
Period after the quarter in which prescription is filled for rebate			1 month	2 months		2 months	3 months